Clinician-Guided Weight Management
Medical Weight Loss With GLP-1 Medications
GLP-1 receptor agonists and related medications can support chronic weight management for eligible patients when combined with nutrition, physical activity, and ongoing medical care. The right option depends on the approved indication, medical history, other medications, treatment goals, and availability.
A licensed clinician reviews contraindications, potential benefits, material risks, and product-specific instructions before prescribing. Results vary, and submitting an intake does not guarantee eligibility or a prescription.
Prescription treatment is subject to medical evaluation, product labeling, state availability, eligibility, and ongoing clinical monitoring.
Slide 1 of 3
Advanced Clinical Weight Loss Programs
These medications act on incretin pathways involved in appetite, food intake, glucose regulation, and gastric emptying. The summaries below describe trials of specific FDA-approved products used with lifestyle intervention; they do not establish equivalent results for compounded products or predict an individual result.
Semaglutide
Once-Weekly InjectionSemaglutide is a GLP-1 receptor agonist. Wegovy is FDA approved for chronic weight management in specific populations and has additional labeled indications. Dosing and eligibility must follow the selected product’s current prescribing information.
In adults without diabetes, semaglutide 2.4 mg weekly plus lifestyle intervention produced an estimated mean 14.9% body-weight reduction at 68 weeks versus 2.4% with placebo. Trial averages are not guarantees.
Tirzepatide
Once-Weekly InjectionTirzepatide is a dual GIP and GLP-1 receptor agonist. Zepbound is FDA approved for chronic weight management in specific populations. It can affect oral hormonal contraceptives after initiation and dose escalation; product-specific counseling is required.
In adults without diabetes, tirzepatide 15 mg plus lifestyle intervention produced a mean 20.9% body-weight reduction at 72 weeks versus 3.1% with placebo. Trial averages are not guarantees.
Liraglutide
Once-Daily InjectionLiraglutide is a daily GLP-1 receptor agonist. Saxenda is FDA approved for chronic weight management in specific populations. Whether a daily option is appropriate depends on the patient and current product labeling.
In adults without diabetes, liraglutide 3.0 mg plus lifestyle intervention produced a mean 8.0% body-weight reduction at 56 weeks versus 2.6% with placebo. Trial averages are not guarantees.
Safety, Side Effects, and Contraindications
GLP-1 and related medications can cause common and serious adverse effects. Risk differs by product, dose, medical history, and other medications. This summary is not a substitute for the current prescribing information or clinician counseling.
Common and Serious Risks
Nausea, vomiting, diarrhea, constipation, and abdominal pain are common. Patients should also be counseled about product-specific warnings and when to seek urgent care:
- Pancreatitis and gallbladder disease
- Acute kidney injury related to dehydration or volume depletion
- Severe gastrointestinal reactions; some products are not recommended in severe gastroparesis
- Hypoglycemia risk when combined with insulin or insulin secretagogues
- Serious hypersensitivity reactions
- Delayed gastric emptying and aspiration risk during anesthesia or deep sedation
- Fetal harm; pregnancy planning requires product-specific guidance
Clinical Contraindications
Current labels for semaglutide, tirzepatide, and liraglutide include important contraindications and warnings. A prescriber must review at least:
- A personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Prior serious hypersensitivity to the selected product or an ingredient.
- Pregnancy, planned pregnancy, or breastfeeding considerations.
- History of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney disease, diabetic retinopathy, and interacting diabetes medications.
- All current medications, upcoming procedures requiring anesthesia, and use of oral hormonal contraceptives when tirzepatide is considered.
A licensed clinician must review your medical history, current medications, pregnancy plans, and individual risk factors. Seek urgent medical care for severe or concerning symptoms.
FDA-Approved and Compounded Medications Are Not Equivalent
Compounded medications are not FDA approved. FDA does not review them for safety, effectiveness, or quality before marketing. They should not be described as the same as an approved product or as a clinically proven substitute.
A clinician may consider a compounded medication only when an individual patient’s medical need cannot be met by an available FDA-approved drug, subject to applicable federal and state law. Product identity, pharmacy, concentration, and instructions must be clearly disclosed.
Important treatment principles include:
Product-Specific Instructions
Dose initiation, escalation, missed-dose guidance, stopping, and switching must follow the selected product’s current label and the prescriber’s instructions. There is no universal switching schedule.
Long-Term Planning
Obesity is a chronic condition. Ongoing treatment duration is individualized, and substantial weight regain can occur after medication withdrawal.
Protecting Overall Health
Weight loss can include both fat and lean mass. Adequate nutrition, resistance activity when appropriate, and clinical monitoring support health, but no TRT combination has been proven to guarantee lean-mass preservation or cardiovascular protection.
Start With a Medical Evaluation
Complete the secure intake, review your history and goals with a licensed clinician, and receive an individualized recommendation. If treatment is appropriate, the clinician explains the selected product, dosing, risks, alternatives, and follow-up plan.
Availability, eligibility, pharmacy fulfillment, and medication shipping vary by state. No specific medication, prescription, or result is guaranteed.
Individual results vary. Compounded medications are not FDA approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.